The following is a summary of “Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs. Jennifer Chan, MD, MPH, ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

The approval was based on the results of the phase 3 CABINET study, which compared cabozantinib to a placebo in patients with advanced pancreatic neuroendocrine tumors and advanced extrapancreatic ...

2-Keto-3-ethoxybutyraldehyde bis(thiosemicarbazone) (KTS) has been shown to have marked carcinostatic and carcinolytic activity against several established rat tumors ...

MONDAY, March 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated advanced ...

A 45-year-old woman from Satara underwent a pioneering surgical procedure in Pune, addressing a rare recurring abdominal wall tumor and a left adrenal adenoma. The hybrid approach utilized robotic ...

Consequently, Cabometyx is now the first and only systemic treatment that is FDA-approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin ...